Drug Patent & Exclusivity Expiration Report - Week of Oct 28 2024 Views: 53 Author: Unibest Industrial Publish Time: 2024-10-28 Origin: Site
Patent and Exclusivity Expirations Report Report generated for the week of 2024-10-28 by Unibest Digital Center. Current analysis scope only include the US FDA.
Summary of Expirations This week, there are 6 drugs in the patent and exclusivity list. They are:
Patents Expiring This Week HEPARIN SODIUM; TAUROLIDINE - SOLUTION;N/A - DEFENCATH From CORMEDIX INC
3,000 UNITS/3ML (1,000 UNITS/ML);40.5MG/3ML (13.5MG/ML) Approved in Nov 15, 2023, used as Reference Listed Drug and Reference Standard
There are 2 future patent(s) for this application. The earliest expires on 2025-05-16, and the latest expires on 2042-04-15.
Patent No Patent Use Code Patent Use Definition Patent Expiration Date 8541393 U-3774 A CATHETER LOCK SOLUTION TO REDUCE CATHETER-RELATED BLOODSTREAM INFECTIONS IN ADULT PATIENTS RECEIVING HEMODIALYSIS THROUGH A CENTRAL VENOUS CATHETER 2024-11-02 9339036 NaN NaN 2024-11-02
5,000 UNITS/5ML (1,000 UNITS/ML);67.5MG/5ML (13.5MG/ML) Approved in Nov 15, 2023, used as Reference Listed Drug and Reference Standard
There are 2 future patent(s) for this application. The earliest expires on 2025-05-16, and the latest expires on 2042-04-15.
Patent No Patent Use Code Patent Use Definition Patent Expiration Date 8541393 U-3774 A CATHETER LOCK SOLUTION TO REDUCE CATHETER-RELATED BLOODSTREAM INFECTIONS IN ADULT PATIENTS RECEIVING HEMODIALYSIS THROUGH A CENTRAL VENOUS CATHETER 2024-11-02 9339036 NaN NaN 2024-11-02
LOXAPINE - POWDER;INHALATION - ADASUVE From ALEXZA PHARMACEUTICALS INC
10MG Approved in Dec 21, 2012, used as Reference Listed Drug and Reference Standard
There are 1 future patent(s) for this application. The earliest expires on 2026-10-23, and the latest expires on 2026-10-23.
Patent No Patent Use Code Patent Use Definition Patent Expiration Date 7537009 NaN NaN 2024-10-28
TICAGRELOR - TABLET;ORAL - BRILINTA From ASTRAZENECA PHARMACEUTICALS LP
60MG Approved in Sep 3, 2015, used as Reference Listed Drug
There are 5 future patent(s) for this application. The earliest expires on 2025-04-30, and the latest expires on 2036-07-27.
Patent No Patent Use Code Patent Use Definition Patent Expiration Date RE46276 U-2838 REDUCTION OF THE RATE OF A FIRST MYOCARDIAL INFARCTION OR STROKE IN PATIENTS WITH CORONARY ARTERY DISEASE AT HIGH RISK FOR SUCH EVENTS 2024-10-30 RE46276 U-2988 REDUCTION OF THE RISK OF STROKE IN PATIENTS WITH ACUTE ISCHEMIC STROKE OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK 2024-10-30 RE46276 U-2839 TREATMENT OF MYOCARDIAL INFARCTION OR STROKE IN PATIENTS WITH CORONARY ARTERY DISEASE AT HIGH RISK FOR SUCH EVENTS 2024-10-30 RE46276 U-1936 TREATMENT OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION 2024-10-30 RE46276 U-1937 TREATMENT OF MYOCARDIAL INFARCTION IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION 2024-10-30 RE46276 U-1938 TREATMENT OF STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION 2024-10-30 RE46276 U-1935 REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION 2024-10-30
90MG Approved in Jul 20, 2011, used as Reference Listed Drug and Reference Standard
There are 5 future patent(s) for this application. The earliest expires on 2025-04-30, and the latest expires on 2036-07-27.
Patent No Patent Use Code Patent Use Definition Patent Expiration Date RE46276 U-2988 REDUCTION OF THE RISK OF STROKE IN PATIENTS WITH ACUTE ISCHEMIC STROKE OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK 2024-10-30 RE46276 U-1935 REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION 2024-10-30 RE46276 U-2839 TREATMENT OF MYOCARDIAL INFARCTION OR STROKE IN PATIENTS WITH CORONARY ARTERY DISEASE AT HIGH RISK FOR SUCH EVENTS 2024-10-30 RE46276 U-1937 TREATMENT OF MYOCARDIAL INFARCTION IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION 2024-10-30 RE46276 U-1938 TREATMENT OF STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION 2024-10-30 RE46276 U-1936 TREATMENT OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION 2024-10-30 RE46276 U-2838 REDUCTION OF THE RATE OF A FIRST MYOCARDIAL INFARCTION OR STROKE IN PATIENTS WITH CORONARY ARTERY DISEASE AT HIGH RISK FOR SUCH EVENTS 2024-10-30
Exclusivities Expiring This Week ACALABRUTINIB - CAPSULE;ORAL - CALQUENCE From ASTRAZENECA UK LTD
100MG Approved in Oct 31, 2017, used as Reference Listed Drug and Reference Standard
There are 1 future exclusivity(ies) for this drug product. The earliest expires on 2026-11-21, and the latest expires on 2026-11-21.
Exclusivity Date Exclusivity Use Definition 2024-10-31 NaN
PILOCARPINE HYDROCHLORIDE - SOLUTION;OPHTHALMIC - VUITY From ABBVIE INC
1.25% Approved in Oct 28, 2021, used as Reference Listed Drug and Reference Standard
There are 1 future exclusivity(ies) for this drug product. The earliest expires on 2026-03-28, and the latest expires on 2026-03-28.
Exclusivity Date Exclusivity Use Definition 2024-10-28 NEW PRODUCT
TERIFLUNOMIDE - TABLET;ORAL - AUBAGIO From SANOFI AVENTIS US LLC
14MG Approved in Sep 12, 2012, used as Reference Listed Drug and Reference Standard
There are no future exclusivities for this application.
Exclusivity Date Exclusivity Use Definition 2024-10-30 PEDIATRIC EXCLUSIVITY
7MG Approved in Sep 12, 2012, used as Reference Listed Drug
There are no future exclusivities for this application.
Exclusivity Date Exclusivity Use Definition 2024-10-30 PEDIATRIC EXCLUSIVITY
